

**Henry C. Barry, MD, MS**

Professor Emeritus, Department of Family Medicine, and Senior Associate Dean Emeritus, College of Human Medicine, Michigan State University, East Lansing

The author reported no potential conflict of interest relevant to this editorial. Dr. Barry is an associate editor for The Journal of Family Practice.

jfp.eic@mdedge.com

doi: 10.12788/jfp.0526

A reason for hope in the face of long COVID

In this issue, Mayo and colleagues¹ summarize what we know about patients with long COVID. The report made me pause and realize that it has been 3 years since we heard the very first reports of patients infected with SARS-CoV-2, which would eventually cause the COVID-19 pandemic. I suspect that I am not alone in having been fascinated by the rapid communication of information (of variable quality and veracity) via peer-reviewed papers, pre-print servers, the media, and social media.

The early studies were largely descriptive, focusing on symptom constellations and outbreak data. Much of what we had by way of treatment was supportive and

**What we know
about long COVID
appears to be
following the early
course of its parent
illness.**

“let’s try anything”—whether reasonable or, in some cases, not. In relatively short order, though, we developed effective vaccines to help protect people from getting seriously ill, being hospitalized, and dying; we also identified targeted therapies for those who became ill.² But variants continued—or rather, continue—to emerge, and we remain committed to meeting the demands of the day.

The Centers for Disease Control and Prevention reports that more than 98 million Americans have contracted COVID, and more than 1 million have died.³ Besides the astonishingly high total mortality, the ravages of COVID-19 include new-onset respiratory, cardiovascular, neurologic, and psychiatric illnesses.^{4,5} As many as half of adults hospitalized for COVID report having persistent symptoms.⁶

As described in this issue, what we know about long COVID appears to be following the early course of its parent illness. As was true then, we are learning about the symptoms, etiology, and best ways to manage our patients. As in the early days of the pandemic, treatment is supportive, and we await definitive therapies.

I am optimistic, though. Why? Because shortly after the first reports of COVID-19, the virus’ DNA sequence was shared online. Based on that information, diagnostic assays were developed. Within 2 years of the outbreak, we had effective vaccines and specific therapies.

■ **Another call to action.** If 5% of patients contracting COVID (a very low estimate) develop long COVID, that would translate to 4.9 million people with long COVID in the United States. That is an astounding burden of suffering that I have no doubt will motivate innovation.

Innovation is a strength of the US health care system. I believe we will rise to the next challenge that COVID-19 has put before us. We have reason to be hopeful.

JFP

CONTINUED

ASSOCIATE EDITORS

HENRY C. BARRY, MD, MS

Professor Emeritus, Department of Family Medicine, and Senior Associate Dean Emeritus, College of Human Medicine, Michigan State University, East Lansing

KATE ROWLAND, MD, MS, FAAFP

Rush University, Chicago

RICHARD P. USATINE, MD

University of Texas Health, San Antonio (Photo Rounds)

ASSISTANT EDITORS

DOUG CAMPOS-OUTCALT, MD, MPA

University of Arizona

RICK GUTHMANN, MD, MPH

Advocate Health Care Illinois Masonic Medical Center Program, Chicago

GARY KELSBERG, MD, FAAFP

University of Washington, Renton

COREY LYON, DO

University of Colorado, Denver

E. CHRIS VINCENT, MD

University of Washington, Seattle

SAMINA YUNUS, MD, MPH

Cleveland Clinic, Chagrin Falls, OH

EDITORIAL BOARD

FREDERICK CHEN, MD, MPH

University of Washington, Seattle

MARK S. JOHNSON, MD, MPH

Howard University College of Medicine Washington, DC

JEFFREY T. KIRCHNER, DO, FAAFP, AAHIVS

Penn Medicine/Lancaster General Hospital, PA

TRACY MAHVAN, PHARM D

University of Wyoming, Laramie

MICHAEL MENDOZA, MD, MPH, MS, FAAFP

University of Rochester, NY

FRED MISER, MD, MA

The Ohio State University, Columbus

MICHAEL RADDOCK, MD

The MetroHealth System, Cleveland, OH

KATE ROWLAND, MD, MS, FAAFP

Rush University, Chicago

LINDA SPEER, MD

University of Toledo, OH

DIRECT INQUIRIES TO:

Frontline Medical Communications
283 - 299 Market St.
(2 Gateway Building), 4th Floor
Newark, NJ 07102
Telephone: (973) 206-3434
Fax: (973) 206-9378

Have a comment or
feedback?

Email: jfp.eic@mdedge.com

References

1. Mayo NL, Ellenbogen RL, Mendoza MD, et al. The family physician's role in long COVID management. *J Fam Pract.* 2022;71:426-431. doi: 10.12788/jfp.0517
2. Kulshreshtha A, Sizemore S, Barry HC. COVID-19 therapy: What works? What doesn't? And what's on the horizon? *J Fam Pract.* 2022;71:E3-E16. doi: 10.12788/jfp.0474
3. CDC. COVID data tracker. Accessed December 5, 2022. <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>
4. Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry.* 2021;8:416-427. doi: 10.1016/s2215-0366(21)00084-5
5. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ.* 2021;372:n693. doi: 10.1136/bmj.n693
6. Writing Committee for the Comebac Study Group, Morin L, Savale L, Pham T, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. *JAMA.* 2021;325:1525-1534. doi: 10.1001/jama.2021.3331

MDedge® | Family Medicine

Providing timely content
and features from

THE JOURNAL OF
**FAMILY
PRACTICE**®

Family Practice News®

in a single web resource

- Breaking news
- Conference coverage
- Expert perspectives
- Health policy, tech, and costs of care
- Features, quizzes, and more

Stay sharp at MDedge.com/FamilyMedicine